Eledon Pharmaceuticals
ELDN
17 hedge funds and large institutions have $18.9M invested in Eledon Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 0 closing their positions.
55% more funds holding
Funds holding: 11 → 17 (+6)
51% more capital invested
Capital invested by funds: $12.5M → $18.9M (+$6.39M)
0.2% less ownership
Funds ownership: 2.41% → 2.21% (-0.2%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$1.33M |
| 2 |
RI
RTW Investments
New York
|
+$1.23M |
| 3 |
Renaissance Technologies
New York
|
+$67.9K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$54.7K |
| 5 |
DC
Derby & Company
Newton,
Massachusetts
|
+$45.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.01K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4.71K |
| 3 |
D.E. Shaw & Co
New York
|
-$3.24K |
| 4 |
BlackRock
New York
|
-$1.33K |
| 5 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$1.33K |
ELDN Hedge Fund Activity: Q1 2018 in Review
17 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2018, worth a combined $18.9M — up 51% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ELDN positions and 0 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $1.33M. The largest seller was Tower Research Capital (TRC), cutting an estimated $5.01K.
- 17 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2018, up from 11 in Q4 2017.
- Funds reported $18.9M of Eledon Pharmaceuticals stock for Q1 2018, up 51% quarter-over-quarter.
- 6 funds opened new Eledon Pharmaceuticals positions in Q1 2018 and 0 closed out, a net change of +6 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2018 was Boxer Capital, an estimated $1.33M added.
- The largest Eledon Pharmaceuticals seller in Q1 2018 was Tower Research Capital (TRC), an estimated $5.01K sold.
Based on aggregated 13F filings for Q1 2018.